Holistic Optical Biomarkers to Transform Dementia Diagnosis (HOpE)
Research type
Research Study
Full title
Holistic Optical Biomarkers to Transform Dementia Diagnosis (HOpE)
IRAS ID
362563
Contact name
Sumeet Mahajan
Contact email
Sponsor organisation
University of Southampton
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
Many neurological diseases present with similar cognitive, behavioural and/or movement symptoms, particularly in the early stages of disease. This hampers accurate diagnosis of dementia and subsequent patient care, which could be substantially improved if a more accurate prognosis can be defined. Neuroimaging-based techniques (e.g. MRI, PET) are now commonly used for diagnosis, but these require sophisticated technology and expertise. Fluid biomarkers are enhancing diagnosis and cerebrospinal cord fluid (CSF) levels of β-amyloid, total tau (t-tau), and phosphorylated tau (p-tau), can help distinguish AD from other dementias but do not yet accurately predict the rate of cognitive decline.
This represents an urgent unmet clinical need. Improved diagnosis will mean more accurate stratification between patients with closely related dementia types, provision of appropriate disease-specific personalised treatment and patient stratification for enrichment of the most suitable patients in drug trials.
Our MX-Raman technique, a pioneering laser-based test for early dementia diagnosis from CSF and blood serum samples. It surpasses current diagnostic methods in discriminatory potential, affordability and efficiency, it represents a breakthrough in medical technology, integrating traditional disciplines of neurology, optics, computer science and biochemistry. This innovation is not just a leap in healthcare quality; it's a paradigm shift, redefining our approach to neurodegenerative diseases.
This project is the product of a unique interdisciplinary collaboration. Clinicians, biomedical scientists, mathematicians and engineers have united their expertise to develop a diagnostic tool that's effective, minimally invasive, user-friendly, and adaptable to diverse settings. The MX-Raman technique, with its unique label-free fingerprinting detection capability, paves the way for newer, more advanced biomarkers, challenging established methodologies and fostering new thinking in the scientific community. It offers the potential for ground-breaking progress in our understanding and management of neurodegenerative diseases, with far-reaching impacts on research, clinical practice, society, and the environment.REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
25/WM/0226
Date of REC Opinion
7 Nov 2025
REC opinion
Favourable Opinion